Background: Drug-eluting stent (DES) is well known as smaller late loss than bare metal stent (BMS) and produce lower incidence of adverse cardiac event, especially in small coronary artery disease. However, it is not clear which percutaneous coronary intervention (PCI) with DES would be better for long-term clinical outcomes than with BMS, or not. Method: In this multi-center retrospective cohort study, two hundred seventy four patients (BMS 145 patients vs. DES 126 patients: Zotalolimus-eluting stent 62 patients, Paclitaxel-eluting stent 64 patients), who had PCI with one 4.0mm stent in single large coronary artery disease, were consecutively enrolled in three centers since Jan. 2004 to Jul. 2007. Adverse cardiac events were assessed at one year after the procedure. Results: The right coronary artery was the culprit vessel in 50.4% of cases. BMS and DES had equivalent reference vessel diameter (3.9짹0.3mm vs. 3.96짹0.3mm; p=0.31). Stent length was longer in DES group (20.7짹5.6mm vs. 19.4짹4.7mm for BMS; p=0.04). One year of clinical follow-up was available in 100%. 94.5% of patients treated with BMS and 95.3% of the patients who received DES were free of major events (p=0.79). There was no stent thrombosis related to index PCI. Also there was no difference of MACE between two types of DES. Conclusion: PCI in large coronary artery disease carries a low risk of adverse clinical events. The clinical outcomes of large coronary artery disease were not affected by type of used stent.